GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro.
Bellyei. Szabolcs S; Schally. Andrew V AV; Zarandi. Marta M; Varga. Jozsef L JL; Vidaurre. Irving I; Pozsgai. Eva E
Key Findings
- All three cancer cell lines expressed GHRH receptors and the SV1 splice variant.
- Treating the cells with the GHRH antagonist MIA‑602 reduced cell viability, invasion, and release of matrix‑metalloproteinases.
- Cell attachment to fibronectin/matrigel and wound‑healing (motility) were markedly decreased.
- MIA‑602 increased caveolin‑1 and E‑cadherin while strongly lowering NF‑kappaB and beta‑catenin levels.
Practical Outcomes
- For biohackers, this research does not provide any actionable protocol for sermorelin or other GHRH‑based supplements. It is an early‑stage, in‑vitro cancer study of a GHRH blocker, not a guidance for dosing, safety, or performance enhancement in healthy people.
Summary
A lab study found that a synthetic molecule that blocks growth‑hormone‑releasing hormone (GHRH) can slow down the growth and spread of cancer cells grown in a dish, but it does not tell us how to use sermorelin (a GHRH‑activating peptide) for health or longevity.
Abstract
We investigated the effect of a GHRH antagonist, MIA-602on the metastatic cascade in vitro of three human cancers, DBTRG-05 glioblastoma, MDA-MB-468 estrogen-independent breast, and ES-2 clear cell ovarian cancer. GHRH receptors and their main splice variant, SV1 were detected on all three cell lines. After treatment with MIA-602, the cell viability decreased significantly, significant inhibition of cell invasion was observed and the release of MMPs was significantly decreased. The attachment of cancer cells to fibronectin and matrigel was severely hindered. Wound-healing experiments demonstrated a reduced cellular motility in all three cell lines. The upregulation of caveolin-1 and E-cadherin,and thepowerful downregulation of NF-kappaB and beta-catenin was detected. Our study suggests that the clinical application of highly potent GHRH antagonists in cancer therapy would be desirable since they inhibit proliferation and metastasis development as well.
Study Information
pubmed
2010
2010-01-12T00:00:00.000Z
10.1016/j.canlet.2009.12.014
50
65